JPS5822009B2 - Method for removing bitterness from oral chlorhexidine preparations - Google Patents

Method for removing bitterness from oral chlorhexidine preparations

Info

Publication number
JPS5822009B2
JPS5822009B2 JP1257076A JP1257076A JPS5822009B2 JP S5822009 B2 JPS5822009 B2 JP S5822009B2 JP 1257076 A JP1257076 A JP 1257076A JP 1257076 A JP1257076 A JP 1257076A JP S5822009 B2 JPS5822009 B2 JP S5822009B2
Authority
JP
Japan
Prior art keywords
chdg
oral
bitterness
lactic acid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP1257076A
Other languages
Japanese (ja)
Other versions
JPS5296719A (en
Inventor
大浜忠広
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to JP1257076A priority Critical patent/JPS5822009B2/en
Publication of JPS5296719A publication Critical patent/JPS5296719A/en
Publication of JPS5822009B2 publication Critical patent/JPS5822009B2/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43Guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 この発明はクロルヘキシジンジグルコネートを含有する
口腔用製剤の苦味除去法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method for removing bitterness from oral preparations containing chlorhexidine digluconate.

クロルヘキシジン(以下CHDGと略記する)ハ1,1
′−へキサメチレンビス(5−<4−クロロフェニル)
ビグアニド〕と称せられるビグアニド化合物で、その性
状は例えばメルク・インデックス第7版第236頁にも
紹介されている通りのものであるが、持続的且つ広分野
の殺菌作用がある為、細菌性疾患の予防剤や防腐剤或は
消毒剤、防臭剤、消炎剤として注目を集めている。
Chlorhexidine (hereinafter abbreviated as CHDG) Ha1,1
'-hexamethylenebis(5-<4-chlorophenyl)
This is a biguanide compound called "Biguanide", and its properties are as introduced in the Merck Index, 7th edition, page 236, but it has a long-lasting bactericidal effect in a wide range of fields, so it is effective against bacterial diseases. It is attracting attention as a preventive agent, preservative, disinfectant, deodorant, and anti-inflammatory agent.

ところが、CHDGの水溶性は極めて低いもので、その
有用性にもかかわらず汎用し難いという欠点があり何ら
かの改善が求められていたところ、ポリヒドロキシ脂肪
族カルボン酸(殊にグルコン酸)を作用させた場合には
極めて高度の水溶性塩に導かれることが判り、CHDG
の実用的価値は相当高いものになっている。
However, the water solubility of CHDG is extremely low, and despite its usefulness, it has the disadvantage of being difficult to use for general purposes.Therefore, some kind of improvement was sought, and it was discovered that CHDG was treated with polyhydroxy aliphatic carboxylic acids (especially gluconic acid). It has been found that when
Its practical value is quite high.

しかるにCHDGの水溶性が向上し水溶液としての適用
範囲が拡大するにつれ、かえって逆の欠点が種々露呈す
る様になっている。
However, as the water solubility of CHDG improves and the range of its application as an aqueous solution expands, various disadvantages are becoming more apparent.

その1つとして、口腔に適用した場合の苦味が挙げられ
る。
One of them is the bitter taste when applied to the oral cavity.

即ち、CHDGは前述の如き作用を有しているので、口
腔用清浄剤例えば口腔用殺菌剤、消炎剤、歯垢防止剤等
に主薬又は補助薬として有用であることが期待され、そ
の使用形態としても含漱剤、塗布剤、トローチ剤、歯み
がき剤等が考えられる。
In other words, since CHDG has the above-mentioned effects, it is expected to be useful as a main agent or an adjunct in oral cleansers, such as oral bactericides, anti-inflammatory agents, anti-plaque agents, etc.; Possible examples include mouthwashes, liniments, lozenges, and toothpastes.

現に例えば口腔衛生学会雑誌第24巻第1号第19〜2
3頁(昭和49年)には、CHDG含有含漱剤並びに塗
布剤の使用例が報告され、歯垢抑制効果(従ってう蝕予
防効果)が顕著であることを知ることができる。
For example, the Journal of the Oral Hygiene Society, Vol. 24, No. 1, No. 19-2.
On page 3 (1971), examples of the use of CHDG-containing mouthwashes and liniments are reported, and it can be seen that they have a remarkable plaque-inhibiting effect (therefore, caries-preventing effect).

また最近、CHDGの口腔における新しい効果としてア
フタ性潰瘍の治療に有効であることも報告されている。
Furthermore, it has recently been reported that CHDG is effective in treating aphthous ulcers as a new effect in the oral cavity.

この様なところから、CHDG含有口腔用製剤は広く利
用されるべきであるにもかかわらず、CHDG殊にその
高水溶性塩たるCHDGジグルコネートが強烈な苦味を
呈するので、口腔用製剤としては繁用されるに至ってい
ない。
For these reasons, although CHDG-containing oral preparations should be widely used, CHDG, especially its highly water-soluble salt CHDG digluconate, has a strong bitter taste, so it is not often used as oral preparations. It has not yet reached the point where it is done.

本発明はこの様な事情に着目してなされたものであって
、その目的は口腔用クロルヘキシジン製剤の苦味を可及
的に除去し得る方法を提供せんとするものである。
The present invention has been made in view of these circumstances, and its purpose is to provide a method for eliminating the bitter taste of oral chlorhexidine preparations as much as possible.

前記目的を達成せしめ得た本発明の構成とは、口腔用ク
ロルヘキシジン製剤中にクロルヘキシジンジグルコネー
ト1重量部に対して0.2重量部以上の乳酸を配合する
様にした点に要旨が存在するものである。
The gist of the structure of the present invention that has achieved the above object is that 0.2 parts by weight or more of lactic acid is blended per 1 part by weight of chlorhexidine digluconate in the oral chlorhexidine preparation. It is something.

CHDGの苦味を減少する為に考えられるもつとも初歩
的な方策は甘味剤例えば糖分を配合して苦味をマスクす
る手段である。
One of the most rudimentary measures that can be considered to reduce the bitterness of CHDG is to mask the bitterness by incorporating sweeteners such as sugar.

しかるにCHDGジグルコネート含有の低濃度溶液では
、甘味剤や糖分で十分な苦味減少効果を得ることができ
たのに反し、口腔内殺菌や歯垢抑制を目的とする比較的
高濃度溶液になると、CHDG特有の苦味は除去するこ
とができなかった。
However, with low concentration solutions containing CHDG digluconate, we were able to obtain sufficient bitterness reduction effects with sweeteners and sugars, whereas in relatively high concentration solutions aimed at oral sterilization and plaque control, CHDG The characteristic bitterness could not be removed.

しかもこの方法は、う蝕防止を大目的とする口腔内清浄
剤では余り推奨できる方策ではない。
Moreover, this method is not very recommended for oral cavity cleansers whose main purpose is to prevent dental caries.

そこで次に口中清涼剤として汎用されているメントール
、ペパーミント及びハツカ油等を用いることによってC
HDGの苦味を抑制することを考え、まずポリエチレン
グリコール(PEG)やエタノールの如き溶媒に対する
前記清涼剤の溶解度を検討したが、いずれの場合もPE
Gに対する溶解度は極めて低く、使用し得る溶媒として
はエタノールがもつとも好都合であることを知った。
Therefore, by using menthol, peppermint, pepper oil, etc., which are commonly used as mouth fresheners, C.
Considering suppressing the bitter taste of HDG, we first investigated the solubility of the above-mentioned coolant in solvents such as polyethylene glycol (PEG) and ethanol, but in both cases, PE
It was found that the solubility in G is extremely low, and that ethanol is convenient as a usable solvent.

この結果を基とし、下記処方1及び処方2に従ってCH
DG含漱剤を調製し、苦味除去効果を調べた。
Based on this result, CH
A DG rinse agent was prepared and its bitter taste removal effect was investigated.

処方I CHDG 1 d、l−メントール(合成品)0.3 エタノール(薬局方)35 水 残余 全 量 100(重量部) 処方2 CHDG 1 ペノぐ−ミントエッセンス 0.6 エタノール(薬局方)35 水 残余 全 量 100(重量部) 処方1及び 方2で得られた含漱剤は原液であるから、
この原液2mlに水を加えて全量101fLlとしくC
HDGの濃度は0.2係)、10人のパネルを無差別に
選んで官能試験を行なったところ、第1表に示す如き結
果が得られた。
Prescription I CHDG 1 d, l-menthol (synthetic product) 0.3 Ethanol (pharmacopoeia) 35 Water Total remaining amount 100 (parts by weight) Prescription 2 CHDG 1 Penogu-mint essence 0.6 Ethanol (pharmacopoeia) 35 Water Total remaining amount: 100 (parts by weight) Since the mouth-containing agents obtained in Formulation 1 and Method 2 are undiluted solutions,
Add water to 2ml of this stock solution to make a total volume of 101fLlC
The concentration of HDG was 0.2), and a sensory test was conducted on a panel of 10 people selected at random, and the results shown in Table 1 were obtained.

即ち清涼感としては処方2にわずかの優位性がみられた
が、いずれにしてもCHDGの苦味を十分にマスクし得
てないことが判明した。
That is, although Formulation 2 was slightly superior in terms of cooling sensation, it was found that in any case, the bitterness of CHDG could not be sufficiently masked.

尚前記清涼剤の添加量を更に増量しても特に有意義な結
果は得られなかった。
Note that even if the amount of the cooling agent added was further increased, no particularly significant results were obtained.

そこで本発明者は他の添加剤による苦味抑制方法を検討
するべく、種々の矯味剤(例えばクエン酸等の酸類等)
を選定し、夫々について前記と同様の実験を行なったが
、それ自身苦味を有しない乳酸がもつとも有効であった
ので、以下乳酸を添加した場合について説明する。
Therefore, the present inventors investigated methods of suppressing bitterness using other additives, using various flavoring agents (for example, acids such as citric acid, etc.).
were selected and experiments similar to those described above were conducted for each of them, but lactic acid, which itself does not have a bitter taste, was found to be most effective, so the case where lactic acid is added will be described below.

第2〜4表はCHDGの使用濃度と乳酸配合量を変化さ
せていった場合の苦味及び酸味の変化を示したもので、
いずれも前記10人のパネルによる官能試験の結果を平
均的に示したものである。
Tables 2 to 4 show the changes in bitterness and sourness when the concentration of CHDG used and the amount of lactic acid blended were changed.
All of these are the average results of the sensory tests conducted by the 10-person panel.

; 第2〜4表の結果を見れば明らかな様に乳酸を添加
しない場合のCHDGの苦味は極めて顕著であるが、乳
酸の添加量が増加するにつれて苦味が徐々に減少し、や
がて苦味は殆んど感じられない様になっている。
; As is clear from the results in Tables 2 to 4, the bitterness of CHDG without the addition of lactic acid is extremely pronounced, but as the amount of lactic acid added increases, the bitterness gradually decreases, and eventually becomes almost completely bitter. It's like I can't feel it anymore.

他方乳酸添加による酸味は必ず−しも苦味の減少に対応
して増加するものではなく、むしろ当初は酸味を生じる
ことなく苦味のみが減少していることは注目すべきこと
である。
On the other hand, it is noteworthy that the sourness caused by the addition of lactic acid does not necessarily increase in response to the decrease in bitterness, but rather that only the bitterness decreases without producing any sourness initially.

そして苦味の実質的抑制を果すに必要な乳酸の量は、C
HDGの濃度によって若干相違し、必ずしも−律的に規
定されるものではないが、一般的口腔剤としては0.2
重量部以上が好ましいと考えられる。
And the amount of lactic acid required to achieve substantial suppression of bitterness is C
Although it varies slightly depending on the concentration of HDG and is not necessarily strictly regulated, a general oral preparation of 0.2
It is considered that parts by weight or more are preferable.

尚最近注目されている菌垢防止用含漱剤ではCHDGの
一般的使用濃度が0,1〜0.5係であるから、CHD
GI重量部に対して0.2重量部以上(更に好ましくは
0.4重量部以上)の乳酸を配合することが推奨される
In addition, the concentration of CHDG generally used in the destaining agent for preventing bacterial plaque, which has recently been attracting attention, is 0.1 to 0.5, so CHD
It is recommended that 0.2 parts by weight or more (more preferably 0.4 parts by weight or more) of lactic acid be blended with respect to GI parts by weight.

他方乳酸配合量の上限であるが、それ自身舌ざわりのよ
い酸味を呈するものであるから多少多いめに配合しても
施用者に不快感を与えることが少ない。
On the other hand, although this is the upper limit of the amount of lactic acid to be blended, since lactic acid itself has a pleasant sour taste, even if a slightly larger amount is blended, it will not cause discomfort to the user.

従って上限については実質上存在しないが、苦味を減少
させることが当初の目的であることや経済性等を考慮す
れば、一応0.8〜1.6重量部程度を上限値の目安と
すればよい。
Therefore, there is virtually no upper limit, but considering the initial purpose of reducing bitterness and economic efficiency, the upper limit should be set at around 0.8 to 1.6 parts by weight. good.

本発明方法の適用される口腔剤としては、含漱剤、塗布
剤、トローチ、歯磨等があるので、単に水溶液として用
いる他、適当な基材が用いられることもあることは当然
である。
Oral preparations to which the method of the present invention can be applied include mouthwashes, liniments, troches, toothpastes, etc., and it goes without saying that in addition to simply being used as an aqueous solution, a suitable base material may also be used.

またその用途に応じて他の成分を配合し得ることは言う
迄もない。
It goes without saying that other ingredients may be added depending on the intended use.

かかる第3成分としては、CHDG以外の口腔剤成分例
えば歯垢抑制剤として公知の抗菌剤や消炎剤、清涼剤等
が例示される。
Examples of the third component include oral preparation components other than CHDG, such as antibacterial agents known as plaque inhibitors, anti-inflammatory agents, and refreshing agents.

この様な第3成分を添加した処方例として下記の如きも
のを調製し前記と同様の官能試験を行なった。
As a formulation example in which such a third component was added, the following formulation was prepared and subjected to the same sensory test as described above.

苦味及び酸味についての結果は第5,6表に示す通りで
あって、第2,3表に示した結果とほぼ一致するがd、
l−メントールやエタノールが配合されているため、芳
香並びに清涼感については更に改善されており含漱剤と
しては一層好都合なものになっている。
The results regarding bitterness and sourness are shown in Tables 5 and 6, and are almost the same as the results shown in Tables 2 and 3.
Since l-menthol and ethanol are blended, the fragrance and refreshing feeling are further improved, making it even more convenient as a rinsing agent.

この様なところから、下記の如き処方例を本発明の実施
例として示すことができる。
From this point of view, the following formulation examples can be presented as examples of the present invention.

処方3 CHDG O,1 乳酸(薬局方) 0.02 エタノール(薬局方) 7 水 残余 全量 100(重量部) 処方4 CHDG O,2 乳酸(薬局方) O,OS エタノール(薬局方) 7 水 残余 全 量 100(重量部) 処方5 CHD G O,4 乳酸(薬局方)0.2 エタノール(薬局方) 7 水 残余 全 量 100(重量部) 処方6 CHDG O,1 乳酸(薬局方) 0.04 d、l−メントール(4飯も昂)0.06エタノール(
薬局方) 7 水 残余 全 量 100(重量部) 処方7 CHDG O,2 乳酸(薬局方) 0.12 d、l−メントール(合部)0.06 エタノール(薬局方) 7 水 残余 全 量 100(重量部) 前記処方のうち処方7によって得た含漱剤を使用して歯
垢生成の抑制率を調べた(対象成人20人)。
Formulation 3 CHDG O,1 Lactic acid (Pharmacopoeia) 0.02 Ethanol (Pharmacopeia) 7 Water Total remaining amount 100 (parts by weight) Formulation 4 CHDG O,2 Lactic acid (Pharmacopoeia) O,OS Ethanol (Pharmacopoeia) 7 Water Residual Total amount 100 (parts by weight) Prescription 5 CHDG O,4 Lactic acid (pharmacopoeia) 0.2 Ethanol (pharmacopoeia) 7 Water Total amount remaining 100 (parts by weight) Prescription 6 CHDG O,1 Lactic acid (pharmacopoeia) 0. 04 d, l-menthol (4 meals) 0.06 ethanol (
Pharmacopoeia) 7 Water Total remaining amount 100 (parts by weight) Prescription 7 CHDG O,2 Lactic acid (Pharmacopeia) 0.12 d, l-menthol (Combined) 0.06 Ethanol (Pharmacopeia) 7 Water Total remaining amount 100 (Parts by weight) The rate of inhibition of dental plaque formation was investigated using the rinsing agent obtained from Formulation 7 of the above formulations (20 adult subjects).

この際前記処方7の含漱剤を1日2回夫々5〜30秒間
口中にいきわたらせてから吐出させたが、特に事後のう
がい(水道水)をしなくとも後味は悪くなかった。
At this time, the gargling agent of Formulation 7 was spread into the mouth for 5 to 30 seconds twice a day and then exhaled, but the aftertaste was not bad even without gargling (with tap water) afterwards.

そして前述の口腔衛生学会雑誌に記載されたのと同様の
検査をしたところ、同様の歯垢抑制効果を確認すること
ができた。
When we conducted a test similar to that described in the above-mentioned Journal of the Oral Health Society, we were able to confirm the same plaque-inhibiting effect.

この発明の方法は前述の如く構成されているので、CE
DGの苦味はほとんど消失されており、且つ含漱等の施
用後の後味も悪くはない。
Since the method of this invention is configured as described above, the CE
The bitter taste of DG has almost disappeared, and the aftertaste after applying rinsing etc. is not bad.

従って特に学童や青少年の如き嗜好性の強い人々に対し
ても嫌われることなく連続して使用させることが可能で
あるので、我が国の口腔衛生対策殊にう蝕予防対策に資
するところは極めて大きいものがある。
Therefore, it can be used continuously without being disliked, especially by people with strong tastes such as school children and young people, so it will greatly contribute to oral hygiene measures in Japan, especially caries prevention measures. There is.

Claims (1)

【特許請求の範囲】[Claims] 1 口腔用クロルヘキシジン製剤中にクロルヘキシジン
ジグルコネート1重量部に対して、0.2重量部以上の
乳酸を配合することを特徴とする口腔用クロルヘキシジ
ン製剤の苦味除去法。
1. A method for removing bitterness from a chlorhexidine preparation for oral use, which comprises blending 0.2 parts by weight or more of lactic acid with respect to 1 part by weight of chlorhexidine digluconate in the chlorhexidine preparation for oral use.
JP1257076A 1976-02-07 1976-02-07 Method for removing bitterness from oral chlorhexidine preparations Expired JPS5822009B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1257076A JPS5822009B2 (en) 1976-02-07 1976-02-07 Method for removing bitterness from oral chlorhexidine preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1257076A JPS5822009B2 (en) 1976-02-07 1976-02-07 Method for removing bitterness from oral chlorhexidine preparations

Publications (2)

Publication Number Publication Date
JPS5296719A JPS5296719A (en) 1977-08-13
JPS5822009B2 true JPS5822009B2 (en) 1983-05-06

Family

ID=11809006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1257076A Expired JPS5822009B2 (en) 1976-02-07 1976-02-07 Method for removing bitterness from oral chlorhexidine preparations

Country Status (1)

Country Link
JP (1) JPS5822009B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183916A (en) * 1978-03-31 1980-01-15 Beecham Inc. Oral compositions
JP2004026725A (en) * 2002-06-26 2004-01-29 Sunstar Inc Solid preparation

Also Published As

Publication number Publication date
JPS5296719A (en) 1977-08-13

Similar Documents

Publication Publication Date Title
US3947570A (en) Oral product
JPH08505876A (en) Low alcohol mouthwash fungicide and germicidal formulation
EP1146852B1 (en) A cosmetic composition based on menthol and menthyl lactate, having little odor and being non-irritating
EP3180090A1 (en) Oral care compositions and regimens
JP2008094772A (en) Liquid composition for oral cavity
WO1996016633A1 (en) Reduced alcohol mouthwash
JP5748626B2 (en) Oral composition
JP5729291B2 (en) Oral composition
JPS5822009B2 (en) Method for removing bitterness from oral chlorhexidine preparations
JP4044748B2 (en) Oral liquid composition
JP3987593B2 (en) Oral composition containing sodium chloride and magnesium chloride
JP3599078B2 (en) Liquid or pasty oral composition for removing tongue coating and method used for removing tongue coating
JPH07196463A (en) Composition for oral cavity
JP2017100965A (en) Oral composition
JP2020169150A (en) Oral composition
JP2006160608A (en) Hair-growing composition
JP7268012B2 (en) oral care composition
WO2019107340A1 (en) Composition for oral use
JP2015086164A (en) Liquid oral composition
WO2013099621A1 (en) Oral composition
KR20190035000A (en) Flavoring composition in use of expressing corn flavor
JPH0995429A (en) Composition containing sodium chloride and used for oral cavity
WO2022137870A1 (en) Composition for oral cavity
JP6439425B2 (en) Liquid oral composition
JP2024091991A (en) Oral Composition